Skip to main content

Day: July 2, 2020

Marimaca Announces Conversion of $12 Million Loan at Subsidiary Level

VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) — Marimaca Copper Corp. (“Marimaca Copper” or the “Company”) (TSX: MARI) is pleased to announce that Greenstone Resources II L.P. (“Greenstone”) has exercised its conversion option (the “Conversion”) pursuant to the US$12.0 million convertible loan facility associated with certain of Marimaca Copper’s subsidiaries, Sociedad Contractual Minera Berta (“SCM Berta”) and Rising Star Copper Limited (“RSC”). These subsidiaries hold an interest in the Nora project, which consists of a processing plant and certain mining concessions, which are not connected to the Marimaca deposit. The conversion occurred at the RSC level, resulting in Greenstone now holding a 75% equity stake in the Nora project and Marimaca Copper holding the remaining 25% interest.As a result of the...

Continue reading

Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes

— Orthopedic co-promotion agreement to conclude in January 2021 —— Significantly improves Pacira economics related to EXPAREL —PARSIPPANY, N.J., July 02, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced that the company has notified DePuy Synthes Sales Inc. that the agreement between the two companies to jointly market and promote the use of EXPAREL® (bupivacaine injectable suspension) for orthopedic procedures in the United States will terminate on January 2, 2021. Under this collaboration, which began in January 2017, DePuy Synthes field representatives, specializing in joint reconstruction, spine, sports medicine, trauma and cranio-maxillofacial procedures, collaborate with the Pacira field teams to support...

Continue reading

MediPharm Labs Sets Date to Release Second Quarter 2020 Financial Results

BARRIE, Ontario, July 02, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release its second quarter financial results for the three and six month period ended June 30, 2020 before markets open on Thursday, August 13, 2020. MediPharm Labs executive management team will also host a conference call and audio webcast on Thursday, August 13, 2020, at 8:30 a.m. eastern time to discuss its financial results and outlook.Conference Call Information:Toll-free number: 833-502-0471 / International number: 236-714-2179 / Conference ID: 7466989Due to higher than normal volumes, participants are asked to dial in approximately...

Continue reading

Harpoon Therapeutics Announces Changes to Board of Directors

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the boardDrs. Luke Evnin and Patrick Baeuerle step down from the Harpoon boardDr. Baeuerle remains as a scientific advisor to the companySOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of veteran biotech executive Joanne Viney, Ph.D., to its board of directors as an independent board member. Current board members, Luke Evnin, Ph.D, and Patrick Baeuerle, Ph.D., will be stepping down from the board. Following these changes, Harpoon’s board will be composed of nine directors.“Jo is an accomplished executive with an impressive track record of scientific achievement and drug...

Continue reading

SCANFIL OYJ:N OMIEN OSAKKEIDEN LUOVUTUS OSANA OPTIO-OHJELMIA 2016(A) JA 2016(B)

SCANFIL OYJ        PÖRSSITIEDOTE    2.7.2020        KLO 14.30Scanfil Oyj on kansainvälinen elektroniikkateollisuuden sopimusvalmistaja ja järjestelmätoimittaja, jolla on yli 40 vuoden kokemus vaativasta sopimusvalmistustoiminnasta. Scanfil tarjoaa asiakkaiden käyttöön laajan palvelukokonaisuuden, joka ulottuu tuotesuunnittelusta tuotteen valmistukseen, materiaalien hallintaan sekä logistisiin ratkaisuihin. Vertikaalisesti integroitu tuotanto ja kokonaisvaltainen toimitusketju luovat pohjan Scanfilin kilpailuvalteille: nopeudelle, joustavuudelle ja luotettavuudelle.Tyypillisiä Scanfilin valmistamia tuotteita ovat mobiili- ja tietoliikenneverkkolaitteet, automaatiojärjestelmien moduulit, taajuusmuuttajat, hissien ohjausjärjestelmät, analysaattorit, erilaiset peli- ja itsepalveluautomaatit sekä hoitoteknologiaan ja säähavainnointiin liittyvät...

Continue reading

Transfer of Own Shares as Part of Scanfil Plc’s Stock Option Programs 2016(A) and 2016(B)

SCANFIL PLC        STOCK EXCHANGE RELEASE    2 JULY 2020   2.30 P.M.Typical Scanfil products include mobile and communications network devices, automation system modules, frequency converters, lift control systems, analysers, various slot and vending machines, and devices related to medical technology and meteorology. Scanfil services are used by numerous international automation, energy, IT and health service providers, as well as companies operating in the field of urbanisation. Scanfil’s network of factories consists of 11 production units in Europe, Asia and North America. The total number of employees is about 3,500.

Continue reading

Rekor Systems Expands Market Opportunities with Mesa Technologies Partnership

COLUMBIA, Md., July 02, 2020 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ:REKR) (“Rekor”), a Maryland-based company providing real-time roadway intelligence through AI-driven decisions, and Mesa Technologies, LLC (“Mesa”) today announced a five-year non-exclusive licensing agreement for the use of Rekor’s intellectual property as part of a school bus stop arm system (“SBSA”). Mesa has installed over 3000 photo enforcement systems world-wide. Above an annual payment to Rekor of $1,120,000, Mesa will be entitled to volume discounts that increase through to 20,000 units. The agreement is in place immediately and will increase Rekor’s market penetration in the state, local government, and international markets.The partnership aims to increase student safety as more than 95,000 motorists run school bus stop-arms each day,...

Continue reading

MPX International Closes First Tranche of Non-Brokered Private Placement Offering for Gross Proceeds of C$4.55 Million

TORONTO, July 02, 2020 (GLOBE NEWSWIRE) — MPX International Corporation (the “Corporation” or “MPX”) (CSE: MPXI) is pleased to announce that it has successfully closed the first tranche of its previously announced non-brokered private placement offering (the “Offering”) of units (the “Units”) of the Corporation. The closing of the first tranche of the Offering resulted in the issuance of 3,348 Units at a price of US$1,000.00 (C$1,360) for aggregate gross proceeds of US$3,348,000 (C$4,553,280).Each Unit consists of one 12% secured convertible debenture of the Corporation (a “Debenture”) in the principal amount of US$1,000.00 (the “Principal Amount”) and 7,000 common share purchase warrants (each, a “Warrant”). The Debentures will have a maturity date of twenty-four (24) months from the date of issuance, subject to certain conversion...

Continue reading

Sandy Spring Bancorp, Inc. to Webcast Second Quarter Earnings Conference Call on July 23, 2020

OLNEY, Md., July 02, 2020 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq: SASR) will announce its second quarter earnings on Thursday, July 23, 2020. The company will hold a conference call that day at 2:00 p.m. (ET) to discuss results and answer questions. The conference call will be webcast live through the Sandy Spring Bank website.  Those who wish to participate in order to ask questions may do so by calling 1-866-235-9910; a password is not necessary.  Those who wish to listen to the call should go to the Investor Relations page of www.sandyspringbank.com and log on 10 minutes ahead of the scheduled start of the call. An internet-based replay will be available on the Investor Relations page of the website until August 7, 2020. A telephone voice replay will also be available during that same time period at 1-877-344-7529....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.